Skip to content
Aprameya Engineering logo

Aprameya Engineering

APRAMEYA NSE
₹120.65 +7.35 (+6.49%)
View as Markdown
MCP
Close 4 Nov 2026 ₹120.65 −161.85 −57.3% 1Y
Start ₹282.50

Key Fundamentals

SMEHealthcare Equipment & SuppliesHealthcare

Price-based figures as of · TTM

ROCE
12.60%
Debt to Equity
0.10
EPS (TTM)
—
Book Value
₹36.45
Market Cap
—
P/E (TTM)
—
P/B
3.31
ROE
7.54%
Dividend Yield
0.00%
EBITDA
₹11.00 Cr
52W High
₹360.00
52W Low
₹75.00
Day Range
₹108.15 – ₹123.45
Volume
36,000

Peer Comparison

Healthcare › Medical Equipment › Medical Equipment & Supplies

Aprameya Engineering peer comparison
Molbio Diagnostics
₹1,381.80123.38₹15,607 Cr11.630.00%13.80%18.00%₹1,077 Cr₹125 Cr
Poly Medicure
₹1,586.8051.04₹15,325 Cr5.180.23%9.02%12.50%₹1,997 Cr₹313 Cr
Fischer Medical Ventures
₹25.2366.39₹1,611 Cr3.610.20%8.91%11.40%₹367 Cr₹24 Cr
Tarsons Products
₹311.10148.85₹1,603 Cr2.610.67%2.44%4.59%₹441 Cr₹11 Cr
Q-Line Biotech
₹527.1524.98₹1,243 Cr2.520.00%26.00%22.40%₹201 Cr₹34 Cr
Laxmi Dental
₹188.7133.64₹1,017 Cr4.270.00%14.80%15.00%₹287 Cr₹31 Cr
Hemant Surgical Industries
₹608.10—₹868 Cr5.640.00%16.90%18.90%——
Aprameya Engineering (this company)
₹120.65—₹219 Cr3.310.00%7.54%12.60%——
Median 8 companies₹419.1358.72₹1,423 Cr3.940.00%11.41%13.80%₹404 Cr₹33 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 84/100

Category scores

Quality
94
Strong
Returns, margins, earnings quality 22% weight
Valuation
51
Average
Cheap vs sector & own history 24% weight
Growth
2
Poor
Sales & profit trajectory 9% weight
Financial Health
79
Strong
Solvency, leverage, coverage 9% weight
Momentum
7
Poor
Trend strength, vol-adjusted 12% weight
Ownership
64
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 368 days.
  • Company's cost of borrowing seems high
  • Working capital days have increased from 232 days to 377 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish748
OscillatorsBearish342
Moving AveragesStrong Bullish406

Key readings

RSI (14)
66.03
Neutral
MACD (12,26,9)
0.18
Bullish
SMA (50)
107.83
Bullish
SMA (200)
175.89
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+16.12%
3Y−11.17%
1Y−59.66%

Net profit

Net profit growth by window
5Y+42.43%
3Y−2.57%
1Y−68.73%

Operating cash flow

Operating cash flow growth by window
5Y+54.47%
3YTurned positive
1YTurned positive

Operating margin· change in pp

Operating margin growth by window
5Y+9.72 pp
3Y+6.91 pp
1Y+1.03 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹12.23 Cr
Mar 2021₹25.93 Cr
Mar 2022₹35.00 Cr
Mar 2023₹78.12 Cr
Mar 2024₹65.16 Cr
Mar 2025₹136 Cr
Mar 2026₹54.75 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹0.65 Cr
Mar 2021₹0.86 Cr
Mar 2022₹7.46 Cr
Mar 2023₹5.45 Cr
Mar 2024₹3.49 Cr
Mar 2025₹16.12 Cr
Mar 2026₹5.04 Cr

Half-yearly Results

₹ Cr
APRAMEYA half-yearly results, ₹ crore
Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
9.27
126
42.14
12.61
Expenses
10.65
101
31.12
13.21
Operating Profit
−1.38
25.78
11.02
−0.6
OPM %
−14.89%
20.39%
26.15%
−4.76%
Other Income
0.28
0.31
0.19
0.29
Interest
1.15
2.03
2.03
1.61
Depreciation
0.05
0.05
0.05
0.05
PBT
−2.3
24.01
9.13
−1.97
Tax %
−24.78%
25.7%
25.96%
−12.18%
Net Profit
−1.73
17.84
6.76
−1.72
EPS (₹)
−0.91
9.37
3.55
−0.9

Profit & Loss

₹ Cr
APRAMEYA profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
12.23
25.93
35
78.12
65.16
136
54.75
Expenses
10.64
23.52
24.95
68.67
58.81
111
44.34
Operating Profit
1.59
2.41
10.05
9.45
6.35
24.4
10.41
OPM %
13%
9.29%
28.71%
12.1%
9.75%
17.98%
19.01%
Other Income
0.09
0.08
0.04
0.21
0.46
0.59
0.49
Interest
0.9
0.87
0.14
2.08
2.11
3.18
3.64
Depreciation
0.07
0.09
0.02
0.08
0.09
0.09
0.09
PBT
0.71
1.53
9.93
7.5
4.61
21.72
7.17
Tax %
8.45%
43.79%
24.87%
27.33%
24.3%
25.78%
29.71%
Net Profit
0.65
0.86
7.46
5.45
3.49
16.12
5.04
EPS (₹)
—
—
5.33
3.89
2.49
8.47
2.65
Div. Payout %
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
APRAMEYA balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3.74
4.34
7
14
14
19.04
19.04
Reserves
0
0
7.45
5.93
9.4
45.22
50.3
Borrowings
4.03
1.48
13.69
28.74
42.05
30.34
7.12
Other Liabilities
6.21
5.09
20.49
13.21
10.19
49.36
5.4
Total Liabilities
13.98
10.91
48.63
61.88
75.64
144
81.86
Fixed Assets
0.69
0.63
1.54
1.49
1.43
1.38
1.39
CWIP
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0.35
Other Assets
13.29
10.28
47.09
60.39
74.21
143
80.12
Total Assets
13.98
10.91
48.63
61.88
75.64
144
81.86

Cash Flow

₹ Cr
APRAMEYA cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.06
3.58
10.41
−13.49
−9.97
−10.64
31.48
Investing
−0.57
0.03
−0.24
−1.83
−1
−0.41
−4.01
Financing
0.54
−3.67
−7.69
13.04
11.11
10.89
−27.65
Net Cash Flow
0.04
−0.06
2.48
−2.28
0.14
−0.16
−0.18
Free Cash Flow
−0.31
3.55
10.38
−13.52
−10.58
−10.89
31.31
CFO/EBITDA
22
173
149
−115
−133
−28
333

Ratios

APRAMEYA financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
182
57.99
278
195
325
320
368
Inventory Days
245
122
455
376
73.78
—
81.04
Days Payable
269
147
1,100
415
146
—
95.38
Cash Conversion Cycle
159
33.13
−367
157
253
320
354
Working Capital Days
39.69
36.32
200
116
153
166
377
ROCE %
—
35.32%
59.31%
24.94%
11.78%
31.12%
12.64%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aprameya Engineering insights

47 extracted metrics across FY20–FY26.

Shareholding Pattern

As of Mar 2026

  • Promoters 74.05%
  • Public 21.07%
  • Others 4.17%
  • DIIs 0.70%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Aprameya Engineering

What does Aprameya Engineering Ltd do?
Incorporated in September 2003, Aprameya Engineering Limited specializes in installing and maintaining Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centers.
Where is Aprameya Engineering Ltd (APRAMEYA) listed?
Aprameya Engineering Ltd trades as APRAMEYA on the NSE.
Which sector does Aprameya Engineering Ltd belong to?
Aprameya Engineering Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the 52-week high and low of Aprameya Engineering Ltd?
Over the last 52 weeks Aprameya Engineering Ltd has traded between ₹75 and ₹360 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Aprameya Engineering Ltd?
Aprameya Engineering Ltd reported a return on equity of 7.54%. Its debt-to-equity ratio is 0.10.

Company Information

Incorporated in September 2003, Aprameya Engineering Limited specializes in installing and maintaining Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centers.

Website aelhealth.com
Listed 1 Aug 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APRAMEYA.md for Aprameya Engineering Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Healthcare Equipment stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month